{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:49:23Z","timestamp":1791262163280,"version":"4.1.0"},"reference-count":39,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Polycystic ovary syndrome (PCOS) affects 10% to 13% of individuals assigned female at birth (AFAB), although a greater prevalence is reported in transgender\/gender diverse individuals (TGD) (23.8-38.8%). Testosterone therapy (TT) in TGD individuals is linked to worsening cardiovascular risk factors (CVRFs). Whether TT induces more adverse cardiometabolic changes in TGD with PCOS than TGD without PCOS remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the effects of TT on CVRF in TGD with and without PCOS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed 373 records to identify 62 TGD with PCOS (withestablished guideline criteria) and 132 age-matched TGD without PCOS. Data included longitudinal anthropometric measurements, hormone and metabolic parameters, and CVRF before and after TT. Group comparison of PCOS vs without PCOS before and after TT was conducted via independent t-tests, Mann\u2013Whitney-U, and Chi-square.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, TGD with PCOS had significantly greater body mass index (BMI), obesity prevalence, and, after controlling for BMI, baseline metformin use. There were no significant differences between TGD with and without PCOS when comparing intra-participant changes after TT. Controlling for BMI, TGD with PCOS on TT exhibited significantly greater hyperlipidemia prevalence, alanine transaminase (ALT) levels, and bioavailable testosterone concentrations than TGD without PCOS on TT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Greater baseline cardiometabolic risk was largely BMI-related in TGD with PCOS compared to TGD without PCOS. Only hyperlipidemia and elevated ALT were more prevalent during TT after adjusting for BMI. These findings support cardiometabolic monitoring during TT in all TGD individuals without significant increased risk with PCOS history.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag032","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T12:39:29Z","timestamp":1769258369000},"page":"2064-2074","source":"Crossref","is-referenced-by-count":2,"title":["Metabolic effects of testosterone therapy in transgender and gender diverse individuals with polycystic ovary syndrome"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5665-0617","authenticated-orcid":false,"given":"Justine","family":"Herndon","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic , Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Anderson","family":"McNeil","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic , Jacksonville, FL 32224 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salym","family":"Winter","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic , Jacksonville, FL 32224 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7108-0499","authenticated-orcid":false,"given":"Alice Y","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic , Jacksonville, FL 32224 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"issue":"11","key":"2026061619574788800_dgag032-B1","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1210\/jc.2017-01643","article-title":"Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis","volume":"102","author":"Maraka","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026061619574788800_dgag032-B2","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine treatment of gender-dysphoric\/gender-incongruent persons: an Endocrine Society* Clinical Practice Guideline","volume":"102","author":"Hembree","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"sup1","key":"2026061619574788800_dgag032-B3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1080\/26895269.2022.2100644","article-title":"Standards of care for the health of transgender and gender diverse people, Version 8","volume":"23","author":"Coleman","year":"2022","journal-title":"Int J Transgender Health"},{"issue":"4","key":"2026061619574788800_dgag032-B4","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.fertnstert.2021.07.1206","article-title":"Ovarian, breast, and metabolic changes induced by androgen treatment in transgender men","volume":"116","author":"Pirtea","year":"2021","journal-title":"Fertil Steril"},{"issue":"4","key":"2026061619574788800_dgag032-B5","doi-asserted-by":"crossref","first-page":"256","DOI":"10.7326\/M17-0577","article-title":"Cardiovascular disease among transgender adults receiving hormone therapy","volume":"167","author":"Streed","year":"2017","journal-title":"Ann Intern Med"},{"issue":"4","key":"2026061619574788800_dgag032-B6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7326\/M17-2785","article-title":"Cross-sex hormones and acute cardiovascular events in transgender persons","volume":"169","author":"Getahun","year":"2018","journal-title":"Ann Intern Med"},{"issue":"10","key":"2026061619574788800_dgag032-B7","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1210\/clinem\/dgad463","article-title":"Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"108","author":"Teede","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061619574788800_dgag032-B8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jpag.2023.09.003","article-title":"Prevalence of polycystic ovarian syndrome in young and adolescent transmasculine patients presenting for gender-affirming care","volume":"37","author":"Rangi","year":"2024","journal-title":"J Pediatr Adolesc Gynecol"},{"issue":"6","key":"2026061619574788800_dgag032-B9","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1089\/trgh.2021.0061","article-title":"The comparison of gender dysphoria, body image satisfaction and quality of life between treatment-naive transgender males with and without polycystic ovary syndrome","volume":"7","author":"Gezer","year":"2022","journal-title":"Transgend Health"},{"issue":"4","key":"2026061619574788800_dgag032-B10","doi-asserted-by":"publisher","first-page":"398","DOI":"10.5603\/EP.a2023.0052","article-title":"Hyperandrogenism-related metabolic changes in drug-na\u00efve transmen compared to cisgender women: a case-controlled study","volume":"74","author":"Erel","year":"2023","journal-title":"Endokrynol Pol"},{"key":"2026061619574788800_dgag032-B11","volume-title":"Reproductive Hormones","author":"Yanes Cardozo","year":"2021"},{"issue":"3","key":"2026061619574788800_dgag032-B12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.dsx.2018.01.006","article-title":"Relationship of polycystic ovarian syndrome with cardiovascular risk factors","volume":"12","author":"Bilal","year":"2018","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"issue":"12","key":"2026061619574788800_dgag032-B13","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1093\/humrep\/dew218","article-title":"The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis","volume":"31","author":"Bozdag","year":"2016","journal-title":"Hum Reprod"},{"issue":"3","key":"2026061619574788800_dgag032-B14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4239\/wjd.v11.i3.66","article-title":"Effects of gender-affirming hormone therapy on insulin resistance and body composition in transgender individuals: a systematic review","volume":"11","author":"Spanos","year":"2020","journal-title":"World J Diabetes"},{"issue":"5","key":"2026061619574788800_dgag032-B15","doi-asserted-by":"crossref","first-page":"e12660","DOI":"10.1111\/and.12660","article-title":"Cross-sex hormone therapy in transgender persons affects total body weight, body fat and lean body mass: a meta-analysis","volume":"49","author":"Klaver","year":"2017","journal-title":"Andrologia"},{"issue":"2","key":"2026061619574788800_dgag032-B16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2337\/dc19-1061","article-title":"Effects of gender-affirming hormone therapy on insulin sensitivity and incretin responses in transgender people","volume":"43","author":"Shadid","year":"2020","journal-title":"Diabetes Care"},{"key":"2026061619574788800_dgag032-B17","doi-asserted-by":"crossref","first-page":"2042018820985681","DOI":"10.1177\/2042018820985681","article-title":"Insulin resistance in transgender individuals correlates with android fat mass","volume":"12","author":"Bretherton","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"6","key":"2026061619574788800_dgag032-B18","doi-asserted-by":"crossref","first-page":"E1107","DOI":"10.1152\/ajpendo.00281.2020","article-title":"Virilizing doses of testosterone decrease circulating insulin levels and differentially regulate insulin signaling in liver and adipose tissue of females","volume":"320","author":"Kothmann","year":"2021","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"2026061619574788800_dgag032-B19","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.fertnstert.2021.03.020","article-title":"Insulin resistance: still an underestimated factor in polycystic ovary syndrome?","volume":"115","author":"Zippl","year":"2021","journal-title":"Fertil Steril"},{"key":"2026061619574788800_dgag032-B20","doi-asserted-by":"crossref","first-page":"100937","DOI":"10.1016\/j.molmet.2020.01.001","article-title":"Metabolic dysfunction in polycystic ovary syndrome: pathogenic role of androgen excess and potential therapeutic strategies","volume":"35","author":"Sanchez-Garrido","year":"2020","journal-title":"Mol Metab"},{"issue":"6","key":"2026061619574788800_dgag032-B21","doi-asserted-by":"crossref","first-page":"565","DOI":"10.4158\/EP-2017-0247","article-title":"Exogenous testosterone does not induce or exacerbate the metabolic features associated with PCOS among transgender men","volume":"24","author":"Chan","year":"2018","journal-title":"Endocr Pract"},{"issue":"1","key":"2026061619574788800_dgag032-B22","first-page":"56","article-title":"Innovations, reviews and proposals on the DSM-5: the case of sexual dysfunctions, gender dysphoria and paraphilic disorders","volume":"47","author":"Campo-Arias","year":"2018","journal-title":"Rev Colomb Psiquiatr (Engl Ed)"},{"issue":"1","key":"2026061619574788800_dgag032-B23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Rotterdam ESHRE\/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS consensus workshop group","year":"2004","journal-title":"Hum Reprod"},{"issue":"2","key":"2026061619574788800_dgag032-B24","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1210\/jc.2003-031287","article-title":"Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry","volume":"89","author":"Wang","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026061619574788800_dgag032-B25","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/000456329503200401","article-title":"The determination of bio-available testosterone","volume":"32","author":"Wheeler","year":"1995","journal-title":"Ann Clin Biochem"},{"key":"2026061619574788800_dgag032-B26"},{"key":"2026061619574788800_dgag032-B27"},{"issue":"6","key":"2026061619574788800_dgag032-B28","first-page":"e13","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"Supplement_1","key":"2026061619574788800_dgag032-B29","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc25-S001","article-title":"1. Improving care and promoting health in populations: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"issue":"24","key":"2026061619574788800_dgag032-B30","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026061619574788800_dgag032-B31","doi-asserted-by":"crossref","unstructured":"Herndon J, McNeil JA, Winter S, Chang AY. Supplemental data for: Metabolic effects of testosterone therapy in transgender and gender diverse individuals with polycystic ovary syndrome. Published online 2025. doi:10.6084\/m9.figshare.30810779","DOI":"10.1210\/clinem\/dgag032"},{"key":"2026061619574788800_dgag032-B32","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cca.2019.09.010","article-title":"Sex hormone-binding globulin and polycystic ovary syndrome","volume":"499","author":"Zhu","year":"2019","journal-title":"Clin Chim Acta"},{"issue":"1","key":"2026061619574788800_dgag032-B33","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1373\/clinchem.2018.288241","article-title":"Effects of gender-affirming hormones on lipid, metabolic, and cardiac surrogate blood markers in transgender persons","volume":"65","author":"Defreyne","year":"2019","journal-title":"Clin Chem"},{"issue":"6","key":"2026061619574788800_dgag032-B34","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1210\/jc.2018-02138","article-title":"Cardiometabolic effects of testosterone in transmen and estrogen plus cyproterone acetate in transwomen","volume":"104","author":"van Velzen","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026061619574788800_dgag032-B35","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"4","key":"2026061619574788800_dgag032-B36","doi-asserted-by":"crossref","first-page":"e005597","DOI":"10.1161\/CIRCOUTCOMES.119.005597","article-title":"Cardiovascular disease risk factors and myocardial infarction in the transgender population","volume":"12","author":"Alzahrani","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"10","key":"2026061619574788800_dgag032-B37","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S2213-8587(21)00185-6","article-title":"Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria","volume":"9","author":"de Blok","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2026061619574788800_dgag032-B38","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10865-019-00102-8","article-title":"Assessing gender identity differences in cardiovascular disease in US adults: an analysis of data from the 2014\u20132017 BRFSS","volume":"43","author":"Caceres","year":"2020","journal-title":"J Behav Med"},{"issue":"6","key":"2026061619574788800_dgag032-B39","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1161\/CIR.0000000000001003","article-title":"Assessing and addressing cardiovascular health in people who are transgender and gender diverse: a scientific statement from the American Heart Association","volume":"144","author":"Streed","year":"2021","journal-title":"Circulation"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag032\/66618029\/dgag032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/7\/2064\/66618029\/dgag032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/7\/2064\/66618029\/dgag032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:57:57Z","timestamp":1781654277000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/7\/2064\/8443989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":39,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,1,28]]},"published-print":{"date-parts":[[2026,6,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag032","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,1,28]]}}}